Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -13.55
- Piotroski Score 1.00
- Grade Neutral
- Symbol (NERV)
- Company Minerva Neurosciences, Inc.
- Price $2.65
- Changes Percentage (-0.75%)
- Change -$0.02
- Day Low $2.64
- Day High $2.68
- Year High $13.49
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.43
- Trailing P/E Ratio -0.73
- Forward P/E Ratio -0.73
- P/E Growth -0.73
- Net Income $-30,005,353
Income Statement
Quarterly
Annual
Latest News of NERV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Gold's tremendous rally is making even long-term bulls a bit nervous
Gold futures hit a record high of $2,684.7 per ounce, driven by central bank buying and Fed rate cuts. Despite optimism, strategists warn of potential short-term pullbacks due to overbuying. Some sugg...
By CNBC | 5 days ago -
Lindsey Graham calls reports of Mark Robinson's 'black Nazi' posts 'beyond unnerving'
Senator Lindsey Graham expressed concerns about North Carolina candidate Mark Robinson's alleged derogatory posts, advising him to defend himself. Robinson denies the claims and plans to stay in the g...
By The Guardian | 1 week ago -
Dale Earnhardt Jr. Opens Up About Nerves of His Potential Last NASCAR Race
NASCAR icon Dale Earnhardt Jr. is preparing for what may be his final race, creating a mix of excitement and nerves. With meticulous preparations and minor tweaks to his car, Earnhardt Jr. aims to per...
By Newsweek | 1 week ago
